fig4

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Figure 4. Applications of inflammation-targeted nanomedicines: (A) plaque stabilization and regression in atherosclerosis; (B) reduction of edema and infarct size after MI; (C) reduction of MIRI; and (D) inhibition of ISR. The schematics summarize preclinical mechanisms and therapeutic effects and do not establish clinical efficacy or patient-level therapeutic benefit. MI: Myocardial infarction; MIRI: myocardial ischemia-reperfusion injury; ISR: in-stent restenosis; ASCVD: atherosclerotic cardiovascular disease; ROS: reactive oxygen species; VEGF-C: vascular endothelial growth factor C; LNPs: lipid nanoparticles; AMPK: AMP-activated protein kinase; VSMC: vascular smooth muscle cell.